Posted by Michael Wonder on 01 Jul 2019
International work-sharing Initiative - niraparib (Zejula)
1 July 2019 - The TGA has approved a new drug for the treatment of some ovarian, fallopian tube, or peritoneal cancers, through an international work sharing initiative.
Niraparib (Zejula) is the third medicine to be registered on the Australian Register of Therapeutic Goods that has been evaluated under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium's New Chemical Entities Work Sharing Initiative.
The ACSS is one of multiple initiatives in which TGA has engaged to meet the needs of the Australian people and provide improved access to the most recent and innovative treatment options.
